OBI Pharma, Inc.
The topic of this article may not meet Wikipedia's general notability guideline. (February 2024) |
This article needs additional citations for verification. (February 2024) |
Native name | 台灣浩鼎生技股份有限公司 |
---|---|
Company type | Public |
TWSE: 4174(TPEx) | |
Industry | Pharmaceuticals |
Founded | 2002 |
Headquarters | 19F., No.3, Yuanqu st., Nangang, Taipei, Taiwan |
Key people | Kung-Yee Liang (Chairman) |
Website | www.obipharma.com |
This section needs expansion. You can help by adding to it. (February 2020) |
OBI Pharma, Inc. (Chinese: 台灣浩鼎生技股份有限公司) (TWSE: 4174) is a bio-pharmaceutical company, based in Nangang District, Taipei, Taiwan.[1][2]
In 2018 it announced that its drug, OBI-3424, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC).[3]
History
[edit]The company was founded by Micheal N.Chang on April 29, 2002.[4] It was formerly a subsidiary of Optimer Pharmaceuticals.
On 9 Feb 2007, its parent company Optimer Pharmaceuticals can buy/sell on Nasdaq Stock Exchange. At that time, its share price was US$8.50 per share.
On 15 May 2012, OBI Pharma, Inc. was approved to become a public company in Taiwan.
On 23 Mar 2015, it can do transaction formally on OTC in Taiwan R.O.C.
Primary Focus
[edit]The company mainly concentrates on the development of the research and development of cancer therapies and high quality drugs.[5]
References
[edit]- ^ "OBI Pharma signs cancer drug deal with HK's Odeon - Taipei Times". www.taipeitimes.com. 2022-02-24. Retrieved 2024-04-19.
- ^ "Odeon Therapeutics acquires China rights to two cancer therapy candidates from Obi Pharma in $200M deal | BioWorld". www.bioworld.com. Retrieved 2024-04-19.
- ^ "FDA grants ODD to OBI Pharma's lead investigational drug candidate". www.biospectrumasia.com. Retrieved 2024-04-19.
- ^ "OBI Pharma Inc. Company & People | 4174". Barron's. Retrieved 2024-02-20.
- ^ "OBI Pharma, Inc | LinkedIn". www.linkedin.com. Retrieved 2024-02-20.